ArticleDoklady. Biochemistry and biophysics2025
ELOVL5 Regulates Ferroptosis in Breast Cancer Cells.
Article in Doklady. Biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ferroptosis Resistance: Redundant Antioxidant Networks Are a Barrier to Cancer Therapy.Antioxidants (Basel, Switzerland) · 2026Review
- The Cuproptosis-Associated AL139023.1/miR-139-5p/ELOVL5 ceRNA Axis Regulates Proliferation, Migration, and Cell Cycle in Esophageal Squamous Cell Carcinoma.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Today, breast cancer (BC) occupies a leading position in prevalence and mortality from oncological diseases among the female population worldwide. Ferroptosis is a special type of cell death associated with peroxidation of intracellular lipids. It is a promising option for the therapy of BC resistant to traditional methods of treatment. The ELOVL5 gene, involved in the elongation of long-chain polyunsaturated fatty acids (LC-PUFA), was previously associated with BC progression. In this work, the effect of ELOVL5 knockdown on the dynamics of ferroptosis induction in MDA-MB-231 cells under the influence of docosahexaenoic acid (DHA) and erastin was investigated. A comparative analysis of changes in the expression of individual genes under the influence of these agents was also carried out. It was shown that a decrease in ELOVL5 expression increases cell sensitivity to both agents, while DHA causes earlier cell death. The protective effect of ferroptosis inhibitors (ferrostatin-1 and deferoxamine) confirmed the involvement of this pathway in the observed effects. Differences in the expression of genes associated with oxidative stress, inflammation and proliferation were also revealed, indicating different molecular trajectories of ferroptosis in cells with different ELOVL5 gene expression. Thus, the present study deepens the understanding of the contribution of the ELOVL5 gene to the regulation of ferroptosis and can be used in the development of targeted therapy for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.